LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Compugen Ltd

Cerrado

1.46 5.8

Resumen

Variación precio

24h

Actual

Mínimo

1.32

Máximo

1.46

Métricas clave

By Trading Economics

Ingresos

-7.4M

-6.1M

Ventas

-16M

1.5M

P/B

Media del Sector

60.333

54.533

BPA

-0.08

Margen de beneficios

-415.84

Empleados

74

EBITDA

-12M

-7.5M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+403.6% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-630M

130M

Apertura anterior

-4.34

Cierre anterior

1.46

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2025, 23:48 UTC

Acciones populares

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 may 2025, 23:07 UTC

Principales Noticias

Fortescue Energy CEO to Resign in Executive Overhaul

22 may 2025, 23:03 UTC

Principales Movimientos del Mercado

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 may 2025, 23:59 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 may 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 may 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2025, 23:23 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

22 may 2025, 23:23 UTC

Charlas de Mercado

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 may 2025, 23:12 UTC

Principales Noticias

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 may 2025, 21:54 UTC

Principales Noticias

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 may 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2025, 20:46 UTC

Adquisiciones, fusiones, absorciones

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 may 2025, 20:39 UTC

Ganancias

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 may 2025, 20:36 UTC

Principales Noticias

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 may 2025, 20:36 UTC

Principales Noticias
Ganancias

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 may 2025, 20:32 UTC

Principales Noticias
Ganancias

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 may 2025, 20:27 UTC

Principales Noticias

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 may 2025, 20:20 UTC

Principales Noticias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 may 2025, 20:17 UTC

Principales Noticias

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 may 2025, 20:16 UTC

Ganancias

Intchains Group 1Q Rev $18.2M >ICG

22 may 2025, 20:15 UTC

Principales Noticias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 may 2025, 20:08 UTC

Principales Noticias
Ganancias

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 may 2025, 20:05 UTC

Principales Noticias

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 may 2025, 20:04 UTC

Ganancias

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 may 2025, 20:04 UTC

Ganancias

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 may 2025, 20:01 UTC

Ganancias

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q Net $68M >WDAY

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q EPS 25c >WDAY

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q Adj EPS $2.23 >WDAY

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

403.6% repunte

Estimación a 12 Meses

Media 7 USD  403.6%

Máximo 10 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.